Citalopram is widely used for treating major depressive disorder, but exhibits substantial inter-individual variation in clinical response. CYP3A4 is one of the cytochrome P450 enzymes (CYP450) involved in the demethylation metabolism of citalopram. Genetic polymorphisms in CYP3A4 may alter the metabolism of citalopram by affecting the enzymatic activity of CYP3A4.
Aim:
This study aims to evaluate the metabolic differences of citalopram between wild-type and 21 CYP3A4 variants identified in the Chinese Han population.
Methods:
An optimized in vitro incubation system was established, consisting of recombinant human CYP3A4 expressed in Spodoptera frugiperda 21 insect cells and citalopram at various concentrations. The incubation was maintained at 37°C for 30 minutes. Citalopram and demethylcitalopram were quantified using high-performance liquid chromatography with fluorescence detection. Michaelis-Menten curves were plotted, and enzyme kinetic parameters were calculated for each CYP3A4 variant.
Results:
Our results showed that most CYP3A4 variants significantly altered citalopram metabolism. Specifically, 12 variants (*3, *4, *5, *9, *10, *16, *19, *23, *28, *31, *33, and *34) showed a 30.83% to 96.06% decrease in intrinsic clearance (CLint) compared to wild-type, while five variants (*2, *11, *14, *17, and *18) exhibited a 13.52% to 448.56% increase (p < 0.05). Four mutants (*15, *24, *29, and *32) demonstrated CLint similar to wild-type.
Conclusion:
This study provides the first systematic data on the impact of CYP3A4 variants on citalopram metabolism, suggesting that CYP3A4 genetic polymorphism plays a significant role in citalopram metabolism, and highlighting its potential value in individualized therapy.
AdachiKOhyamaKTanakaY, et al. (2023) High hepatic and plasma exposures of atorvastatin in subjects harboring impaired cytochrome P450 3A4*16 modeled after virtual administrations and possibly associated with statin intolerance found in the Japanese adverse drug event report database. Drug Metabolism and Pharmacokinetics49: 100486.
2.
AmerioABertuccioPSantiF, et al. (2022) Gender differences in COVID-19 lockdown impact on mental health of undergraduate students. Frontiers in Psychiatry12: 813130.
3.
ArendseLBBlackburnJM (2018) Effects of polymorphic variation on the thermostability of heterogenous populations of CYP3A4 and CYP2C9 enzymes in solution. Scientific Reports8(1): 11876.
4.
ArendseLBlundellTBlackburnJ (2013) Combining in silico protein stability calculations with structure-function relationships to explore the effect of polymorphic variation on cytochrome P450 drug metabolism. Current Drug Metabolism14(7): 745–763.
5.
BaharMALantingPBosJHJ, et al. (2020) Impact of drug-gene-interaction, drug-drug-interaction, and drug-drug-gene-interaction on (es)Citalopram therapy: The pharmlines initiative. Journal of Personalized Medicine10(4): 256.
6.
BenkaidaliLAndréFMoroyG, et al. (2019) Four major channels detected in the Cytochrome P450 3A4: A step toward understanding its multispecificity. International Journal of Molecular Sciences20(4): 987.
7.
BousmanCAStevensonJMRamseyLB, et al. (2023) Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin reuptake inhibitor antidepressants. Clinical Pharmacology & Therapeutics114(1): 51–68.
8.
CaLShKTaK, et al. (1995) CYP3A4 expressed by insect cells infected with a recombinant baculovirus containing both CYP3A4 and human NADPH-cytochrome P450 reductase is catalytically similar to human liver microsomal CYP3A4. Archives of Biochemistry and Biophysics319(1):157–167.
9.
CacciaS (1998) Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clinical Pharmacokinetics34(4): 281–302.
10.
CaiYLinQJinZ, et al. (2021) Evaluation of recombinant CYP3A4 variants on the metabolism of oxycodone in vitro. Chemical Research in Toxicology34(1): 103–109.
11.
ChenRAmirghasemiFMaH, et al. (2023) Toward personalized treatment of depression: An affordable Citalopram test based on a solid-contact potentiometric electrode for at-home monitoring of the antidepressant dosage. ACS Sensors8(10): 3943–3951.
12.
COVID-19 Mental Disorders Collaborators (2021) Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet (London, England)398(10312): 1700–1712.
13.
DaiDTangJRoseR, et al. (2001) Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. The Journal of Pharmacology and Experimental Therapeutics299(3): 825–831.
14.
EilertsenJSchnellSWalcherS (2024) The Michaelis-Menten reaction at low substrate concentrations: Pseudo-first-order kinetics and conditions for timescale separation. Bulletin of Mathematical Biology86(6): 68.
15.
EkroosMSjögrenT (2006) Structural basis for ligand promiscuity in cytochrome P450 3A4. Proceedings of the National Academy of Sciences103(37): 13682–13687.
16.
FangPTangP-FXuR-A, et al. (2017) Functional assessment of CYP3A4 allelic variants on lidocaine metabolism in vitro. Drug Design, Development and Therapy11: 3503–3510.
17.
FarajPStørsetEHoleK, et al. (2023) Pro-arrhythmic effect of escitalopram and citalopram at serum concentrations commonly observed in older patients – A study based on a cohort of 19,742 patients. EBioMedicine95: 104779.
GaletinABrownCHallifaxD, et al. (2004) Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates. Drug Metabolism and Disposition: The Biological Fate of Chemicals32(12):1411–1420.
20.
Global Burden of Disease Study 2013 Collaborators (2015) Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (London, England)386(9995): 743–800.
21.
GuttmanYNudelAKeremZ (2019) Polymorphism in cytochrome P450 3A4 is ethnicity related. Frontiers in Genetics10: 224.
22.
HanMQianJYeZ, et al. (2021) Functional assessment of the effects of CYP3A4 variants on acalabrutinib metabolism in vitro. Chemico-Biological Interactions345: 109559.
23.
HanMZhangXYeZ, et al. (2021) Functional evaluation of vandetanib metabolism by CYP3A4 variants and potential drug interactions in vitro. Chemico-Biological Interactions350: 109700.
24.
HannaIHTeiberJFKokonesKL, et al. (1998) Role of the alanine at position 363 of cytochrome P450 2B2 in influencing the NADPH- and hydroperoxide-supported activities. Archives of Biochemistry and Biophysics350(2): 324–332.
25.
HeYQSzklarzGDHalpertJR (1996) Interconversion of the androstenedione hydroxylase specificities of cytochromes P450 2B4 and 2B5 upon simultaneous site-directed mutagenesis of four key substrate recognition residues. Archives of Biochemistry and Biophysics335(1): 152–160.
26.
HuG-XDaiD-PWangH, et al. (2017) Systematic screening for CYP3A4 genetic polymorphisms in a Han Chinese population. Pharmacogenomics18(4): 369–379.
27.
HuXYuanLFangP, et al. (2016) Effect of CYP2D6 genetic polymorphism on the metabolism of citalopram in vitro. Drug Metabolism and Pharmacokinetics31(2): 133–138.
28.
Ingelman-SundbergMSimSCGomezA, et al. (2007) Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacology & Therapeutics116(3): 496–526.
29.
Ishtiak-AhmedKMuslinerKLChristensenKS, et al. (2024) Real-world evidence on clinical outcomes of commonly used antidepressants in older adults initiating antidepressants for depression: A nationwide Cohort Study in Denmark. The American Journal of Psychiatry181(1): 47–56.
30.
KangYParkSYimC, et al. (2009) The CYP3A4*18 genotype in the cytochrome P450 3A4 Gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density. Clinical Pharmacology & Therapeutics85(3): 312–318.
31.
KobayashiKChibaKYagiT, et al. (1997) Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. The Journal of Pharmacology and Experimental Therapeutics280(2): 927–933.
32.
LambaJKLinYSThummelK, et al. (2002) Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics12(2): 121–132.
33.
LiQWangJWangZ-L, et al. (2023) The impacts of CYP3A4 genetic polymorphism and drug interactions on the metabolism of lurasidone. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie168: 115833.
34.
LundmarkJBengtssonFNordinC, et al. (2000) Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatrica Scandinavica101(5): 354–359.
35.
MaekawaKHarakawaNYoshimuraT, et al. (2010) CYP3A4 * 16 and CYP3A4 * 18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs. Drug Metabolism and Disposition38(12): 2100–2104.
36.
MilneRJGoaKL (1991) Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs41(3): 450–477.
37.
MiyazakiMNakamuraKFujitaY, et al. (2008) Defective activity of recombinant Cytochromes P450 3A4.2 and 3A4.16 in oxidation of Midazolam, Nifedipine, and Testosterone. Drug Metabolism and Disposition36(11): 2287–2291.
38.
MolenaarNMBaisBLambregtse-van den BergMP, et al. (2020) The international prevalence of antidepressant use before, during, and after pregnancy: A systematic review and meta-analysis of timing, type of prescriptions and geographical variability. Journal of Affective Disorders264: 82–89.
39.
NakajimaYYoshitaniTFukushima-UesakaH, et al. (2006) Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer. Clinical Pharmacology and Therapeutics80(2): 179–191.
40.
PompiliMSerafiniGDel CasaleA, et al. (2009) Improving adherence in mood disorders: The struggle against relapse, recurrence and suicide risk. Expert Review of Neurotherapeutics9(7): 985–1004.
41.
Pratt-HyattMZhangHSniderNT, et al. (2010) Effects of a commonly occurring genetic polymorphism of human CYP3A4 (I118V) on the metabolism of Anandamide. Drug Metabolism and Disposition38(11): 2075–2082.
42.
SaiKSaitoYFukushima-UesakaH, et al. (2008) Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients. Cancer Chemotherapy and Pharmacology62(3): 529–537.
43.
SevrioukovaIFPoulosTL (2017) Structural basis for regiospecific midazolam oxidation by human cytochrome P450 3A4. Proceedings of the National Academy of Sciences of the United States of America114(3): 486–491.
44.
SheltonRCParikhSVLawRA, et al. (2020) Combinatorial pharmacogenomic algorithm is predictive of Citalopram and Escitalopram metabolism in patients with major depressive disorder. Psychiatry Research290: 113017.
45.
UncetaNGoicoleaMABarrioRJ (2011) Analytical procedures for the determination of the selective serotonin reuptake inhibitor antidepressant citalopram and its metabolites. Biomedical Chromatography25(1–2): 238–257.
46.
von MoltkeLLGreenblattDJGrassiJM, et al. (1999) Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. Biological Psychiatry46(6): 839–849.
47.
WangAYuB-NLuoC-H, et al. (2005) Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients. European Journal of Clinical Pharmacology60(12): 843–848.
48.
WerkANCascorbiI (2014) Functional gene variants of CYP3A4. Clinical Pharmacology and Therapeutics96(3): 340–348.
49.
WillettsJLippaABeerB (1999) Clinical development of citalopram. Journal of Clinical Psychopharmacology19(5 Suppl 1): 36S–46S.
50.
WilliamsPACosmeJSridharV, et al. (2000) Mammalian microsomal cytochrome P450 Monooxygenase: Structural adaptations for membrane binding and functional diversity. Molecular Cell 5(1):121–131.
51.
WilliamsPACosmeJVinkovićDM, et al. (2004) Crystal structures of human cytochrome P450 3A4 Bound to Metyrapone and Progesterone. Science305(5684): 683–686.
52.
XuR-AWenJTangP, et al. (2018) Functional characterization of 22 CYP3A4 protein variants to metabolize Ibrutinib In Vitro. Basic & Clinical Pharmacology & Toxicology122(4): 383–387.
53.
YangC-CZhengXLiuT-H, et al. (2019) Functional characterization of 21 CYP3A4 variants on amiodarone metabolism in vitro. Xenobiotica; the Fate of Foreign Compounds in Biological Systems49(1): 120–126.
54.
YanoJKWesterMRSchochGA, et al. (2004) The structure of human microsomal cytochrome P450 3A4 Determined by X-ray Crystallography to 2.05-Å Resolution. Journal of Biological Chemistry279(37): 38091–38094.
55.
ZawairaAChingLYCoulsonL, et al. (2011) An expanded, unified substrate recognition site map for mammalian cytochrome P450s: Analysis of molecular interactions between 15 mammalian CYP450 isoforms and 868 substrates. Current Drug Metabolism12(7): 684–700.
56.
ZhangXLiQZhouQ, et al. (2023) Determine the enzymatic kinetic characteristics of CYP3A4 variants utilizing artemether-lumefantrine. Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association181: 114065.
57.
ZhouX-YHuX-XWangC-C, et al. (2019) Enzymatic activities of CYP3A4 Allelic variants on Quinine 3-Hydroxylation In Vitro. Frontiers in Pharmacology10: 591.
58.
ZhouQYuXShuC, et al. (2011) Analysis of CYP3A4 genetic polymorphisms in Han Chinese. Journal of Human Genetics56(6): 415–422.
